Document is current
Any future updates will be listed below
-
Authors
Kashiura, Masahiro https://orcid.org/0000-0002-1989-656X
Yasuda, Hideto
Kishihara, Yuki
Tominaga, Keiichiro
Nishihara, Masaaki
Hiasa, Ken-ichi
Tsutsui, Hiroyuki
Moriya, Takashi
-
Funding
Funding for this research was provided by:
Actelion Pharmaceuticals
Mitsubishi Tanabe Pharma Corporation
Nippon Boehringer Ingelheim
Japan Tabacco
Daiichi-Sankyo
IQVIA Service Japan
Omron Healthcare
- License Information
-
More Information
Article History
Received: 4 January 2022
Accepted: 28 March 2022
First Online: 11 April 2022
Declarations
:
: The registry protocol was approved by the Institutional Review Board of each participating hospital. The list of participating hospitals and approval numbers for the Institutional Review Board of each institution are provided in Additional file . Informed consent was waived because of the observational study design that posed minimal risk to patients and preserved their anonymity. An opportunity to opt out from the registry was provided for patients and their respective families.
: Not applicable. No individual patient data will be reported.
: Masahiro Kashiura, Hideto Yasuda, Yuki Kishihara, Keiichiro Tominaga, Masaaki Nishihara, Ken-ichi Hiasa, and Takashi Moriya each declare that they have no conflict of interest. Hiroyuki Tsutsui reports grants from Daiichi Sankyo, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, IQVIA Services Japan, Omron Healthcare, and MEDINET; personal fees from Daiichi Sankyo, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, AstraZeneca, Ono Pharmaceutical, Otsuka Pharmaceutical, Novartis Pharma, Bayer Yakuhin, Pfizer Japan, Bristol-Myers Squibb, Kowa, and Nippon Rinsho outside the submitted work. Hiroyuki Tsutsui is the President of the Japanese Heart Failure Society.
